MarketInOut Stock Screener Log In | Sign Up
 

Agenus Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/28/2026 16:00
Agenus Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization383.88 mln
Float44.48 mln
Earnings Date11/10/2026

EPS

3.03
Solid

P / E

3.11
Deeply undervalued

Piotroski F-Score

6 / 9
Solid

Beneish M-Score

21.05
Highly suspicious

1-Year Forecast

26.33
Transformational upside

Relative Strength

98 / 100
Top performer

Business Description

Agenus Inc. is a US-based biotechnology company focused on developing treatments that use the body's immune system to fight cancer and infectious diseases. Founded in 1994 and headquartered in Lexington, Massachusetts, the company has built a broad pipeline of experimental drugs, several of which are currently in clinical trials. Agenus works alongside major pharmaceutical partners including Bristol-Myers Squibb, Merck, Gilead Sciences, and Incyte Corporation to advance these treatments toward patients.

Key Fundamentals

EPS3.03
P/E3.11
ROE-38.12
RPS3.64
ROIC13.11
ROA45.77
Interest Cover0.61
EBITDA, mln156
EV / EBITDA2.31
EV / EBIT2.38
Revenue, mln133
EV / Revenue2.71

Quote Details

Last 9.43
Change 0.89 (10.42%)
Open 8.71
Volume 2,756,160
Turnover 25,990,590
Average Volume 989,721

Financial Ratios

Pre-Tax Profit Margin69
Current Ratio0.34
Price / Sales2.11
PEG Ratio1.44

Financial Strength

Altman Z-Score-14.24
Piotroski F-Score 6 / 9
Beneish M-Score21.05
1-Year Target Price26.33
Short Ratio5.10
Short % of Float15.04

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 13.21% 98 / 100   
1 Month 20.74% 97 / 100   
2 Months 210% 100 / 100   
6 Months 178% 99 / 100   
1 Year 142% 97 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us